TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: High Dose Dexamethasone as Pain Treatment After Arthroscopic Shoulder Surgery: A Randomised, Blinded Clinical Trial
Brief Summary: The purpose of this study is to determine if a dose of 40 mg dexamethasone is more effective as pain treatment than the currently used dose of 8 mg after arthroscopic shoulder surgery.


Options:
A: Inclusion Criteria:

* Patients having an abdominal hysterectomy on a benign indication.
* Patients who speak and understand Danish.
* Patients who can give informed consent.

Exclusion Criteria:

* Diabetics
* Regular use of glucocorticoids, opioids or tranquilizers
* Regular treatment with immunosuppressives
* Alcohol or drug abuse
* Morphine intolerance
* Age under 18
* Chronic pain disease eg fibromyalgia, rheumatoid arthritis
* Malign indication for hysterectomy
* BMI over 35
* Decreased kidney function
* ASA III or IV
B: Inclusion Criteria:

* Arthroscopic subacromial decompression and/or acromioclavicular resection
* General anaesthesia
* Daysurgery, Horsens Hospital

Exclusion Criteria:

* Incompetent
* Pregnant
* Age under 18 or over 90 years
* Allergy toward dexamethasone
* Diabetes
* Active gastric ulcer
* Untreated hypertension
* Glaucoma
* Daily use of glucocorticoids or strong opioids
* Daily use of analgesics for unrelated illness
* Myasthenia gravis
* Mitochondrial disorders
C: Inclusion Criteria:

* Patient is at least 18 years of age.
* Patient is scheduled to undergo open abdominal surgery requiring overnight hospital stay (24-hour hospital stay after end of surgery).
* Patient is scheduled to receive general anesthesia.
* Patient is scheduled to receive postoperative opioids.
D: Inclusion Criteria:

* Age 18 or older with an American Society of Anesthesiologists (ASA) physical status of I to II
* Scheduled for vitrectomy under local anesthesia

Exclusion Criteria:

* Hypersensitivity to study drug or rescue medication
* Preoperative score for nausea greater than 4 out of 10 points
* Subjects who suffer from chronic nausea and/or vomiting
* Severe hepatic insufficiency (Child-Pugh score \> 9)
* Other antiemetic within 12 hours prior to surgery
* Patients unable to undergo a local anesthetic
* Subjects with clinically significant or unstable cardiac, respiratory, hepatic, renal, or other major organ system disease
* Psychotic illness or depression
* Addiction to illicit substances or alcohol
* Non-psychotic emotional disorders
* Pregnant or lactating
* Subjects who, in the opinion of the investigator, would experience an unacceptable risk from administration of study drug

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: High Dose Dexamethasone as Pain Treatment After Arthroscopic Shoulder Surgery: A Randomised, Blinded Clinical Trial
Brief Summary: The purpose of this study is to determine if a dose of 40 mg dexamethasone is more effective as pain treatment than the currently used dose of 8 mg after arthroscopic shoulder surgery.


Options:
A: Inclusion Criteria:

* Colon resection expected to last \>2 and \<6 hours

Exclusion Criteria:

* Bowel obstruction
* Fever
B: Inclusion Criteria:

* Arthroscopic subacromial decompression and/or acromioclavicular resection
* General anaesthesia
* Daysurgery, Horsens Hospital

Exclusion Criteria:

* Incompetent
* Pregnant
* Age under 18 or over 90 years
* Allergy toward dexamethasone
* Diabetes
* Active gastric ulcer
* Untreated hypertension
* Glaucoma
* Daily use of glucocorticoids or strong opioids
* Daily use of analgesics for unrelated illness
* Myasthenia gravis
* Mitochondrial disorders
C: Inclusion Criteria:

1. Age ≥40 years old.
2. Major non-cardiac surgical procedures scheduled to take ≥ two hours done under general anesthesia.
3. Written informed consent

Exclusion Criteria:

1. Recent intravenous or oral steroid therapy (within 30 days); inhaled steroids are permitted
2. Any contraindications to the proposed interventions
3. ASA Physical Status \> 4
4. Non English speaking patients
5. Procedures done under regional anesthesia
D: Inclusion Criteria:

* patients planned for elective laparoscopic hernia repair (TAPP)
* Unilateral inguinal or femoral hernia
* ASA class I-II
* Read and speak Danish

Exclusion Criteria:

* Acute hernia operation
* Operation for other hernias with mesh during the same procedure
* Endocrine disease (diabetes, adrenal insufficiency etc.)
* fever/infection within the first 10 days before operation
* Poor compliance
* No signed consent form
* Daily intake of opioids or anxiolytic drugs
* Manic episodes
* Use medicine against glaucoma
* Use thiazide or loop diuretics
* Vaccination within the last 14 days

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: High Dose Dexamethasone as Pain Treatment After Arthroscopic Shoulder Surgery: A Randomised, Blinded Clinical Trial
Brief Summary: The purpose of this study is to determine if a dose of 40 mg dexamethasone is more effective as pain treatment than the currently used dose of 8 mg after arthroscopic shoulder surgery.


Options:
A: Inclusion Criteria:

* Patients undergoing lumbar disc surgery in general anaesthesia.
* Patients who have given their written consent to participate and understand the contents of the protocol.
* ASA 1-3.
* BMI \> 18 og \< 40.
* Fertile women need a negative HCG urine test.

Exclusion Criteria:

* Patients who cannot cooperate to the study.
* Patients who do not speak and/or understand Danish.
* Fertile women with a positive HCG urine test.
* Allergy to the drugs used in the trial.
* Alcohol or medicine abuse, assessed by investigator.
* Patients who have had spine surgery before.
* Daily use of strong opioids (morphine, ketobemidone, oxynorm, methadone, fentanyl)
* Daily oral steroid treatment.
B: Inclusion Criteria:

* Arthroscopic subacromial decompression and/or acromioclavicular resection
* General anaesthesia
* Daysurgery, Horsens Hospital

Exclusion Criteria:

* Incompetent
* Pregnant
* Age under 18 or over 90 years
* Allergy toward dexamethasone
* Diabetes
* Active gastric ulcer
* Untreated hypertension
* Glaucoma
* Daily use of glucocorticoids or strong opioids
* Daily use of analgesics for unrelated illness
* Myasthenia gravis
* Mitochondrial disorders
C: Inclusion Criteria:

* Scheduled for a diagnostic laparoscopy for suspected appendicitis
* ASA clas I-III

Exclusion Criteria:

* Known inflammatory bowel disease
* Known autoimmune disease.
* Chronic pain patient.
* Pregnant or breastfeeding.
* In treatment with systemic corticoid steroids or immune-depressants.
* Known glaucoma.
* Known ocular herpes simplex.
* Vaccination within 14 days prior to inclusion.
* Known cushing's disease.
* Known myasthenia gravis.
* Presumably poor compliance with study protocol.
D: Inclusion Criteria:

* Patients undergoing thyroid surgery for benign disease

Exclusion Criteria:

* Depression
* Chronic pain disorder
* Insulin dependent diabetes mellitus
* History of PONV
* Pregnancy
* Age \< 18 years
* Received antiemetic therapy within 48 hours

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis
Brief Summary: The purpose of this study is to evaluate the efficacy of an active rehabilitation program on disability and quality of life of patients affected by dermatomyositis and polymyositis.


Options:
A: Inclusion Criteria:

* diagnosis of Dermatomyositis ore polymyositis according to the International Myositis Assessment and Clinical Studies Group
* functional impairment (an HAQ score greater than 0.5)
* stability of muscle impairment
* medical insurance

Exclusion Criteria:

* no recent inflammatory activity
* other chronic disease
* cognitive impairment
* patients who participated to a rehabilitation program before inclusion
B: Inclusion Criteria:

* formal diagnosis of muscular disease, either FascioScapuloHumeral Dystrophy (FSHD), Inclusion Body Myositis (IBM), Mitochondrial Myopathy (MM) or any other;
* being severely fatigued
* being cardiopulmonary stable and capable of aerobic training (as determined using a submaximal cycling exercise test with ECG (electrocardiography) and advice from a consultant cardiologist and pulmonologist);
* being motivated, committed to the program, and 'ready to change' which is discussed with the patient during the screening by a rehabilitation physician and an occupational therapist; to this end, motivational interviewing will be used (including a advantages/disadvantages matrix; a visual analogue scale (VAS) to rate the importance of participation in de program; and a VAS to rate the confidence a patient has that participation in the program is feasible)
* being able to formulate at least 3 individual participation goals during the interview with the occupational therapist.

Exclusion Criteria:

* active depression or other psychiatric disorder as indicated by a consultant psychologist or by the medical history,
* pregnancy,
* severe co-morbid condition,
* having participated in the Energetic program before
* a travel distance perceived as too burdensome
C: Inclusion Criteria:

* Physically inactive
* Stable drugs regime for at least three months

Exclusion Criteria:

* Other rheumatic diseases
* Physical disability that prevent the patient to perform the physical tests
* Severe pulmonary disease
D: Inclusion Criteria:

* Patients with chronic, stable polymyositis or dermatomyositis with diagnosis of definite or probable polymyositis or dermatomyositis (Bohan and Peter 1975)
* Age 18-80 years
* Duration since diagnosis \> 6 months
* Exercising \< once a week,
* Stable disease activity and medication for at least one month.

Ten healthy controls matched for age, gender and physical exercise level will be included.

-

Exclusion Criteria:

* Severe pulmonary fibrosis
* Heart or lung conditions that contraindicate vigorous exercise
* Severe osteoporosis
* Not being able to perform the exercise program.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Assessment of Inflammatory Markers and Pregnancy Outcomes in Vitamin D-Supplemented Women at Risk of Vitamin D Deficiency: A Double-Blind, Randomized Controlled Trial
Brief Summary: Researchers at the USDA Western Human Nutrition Research Center and clinicians at UC Davis Medical Center are currently conducting a study on the effects of vitamin D supplementation during pregnancy on maternal health and immune function. The investigators believe that vitamin D supplementation at levels greater than the current recommendation is beneficial for maternal health during pregnancy. In particular, there is evidence that vitamin D deficiency during pregnancy puts women at greater risk for diseases like pre-eclampsia, which may be due to an imbalance in immune function at the placenta. This randomized, double-blind study is designed to test this hypothesis. Pregnant women who participate in the study receive either 400 IU or 2,000 IU of vitamin D per day for the duration of their pregnancy. The investigators will collect blood at three time points during pregnancy (16-20 weeks, 26-28 weeks, 36 weeks gestation) for analysis of immune function and vitamin D status. The investigators are also collecting data on clinical parameters, such as blood pressure and glucose tolerance.


Options:
A: Inclusion Criteria:

* Pregnant women
* Less than 20 weeks gestation
* Over 18 years of age
* Able to swallow nutritional supplements

Exclusion Criteria:

* Use of medications known to affect vitamin D metabolism
* Diagnosis of type 1 diabetes
* History of thyroid, renal, or liver disease
* Problems with digestion or absorption
B: Inclusion Criteria:

* Women aged ≥18 years old
* HIV-positive
* Receiving HAART
* Pregnant and of 12-27 weeks gestation (Second Trimester)
* Calcium levels in the normal physiologic range (≤2.6 mmol/L)

Exclusion Criteria:

* Enrolled in any other clinical trial
C: Inclusion Criteria:

* Infants born to women enrolled in the MDIG trial (NCT01924013).
* Maternal inclusion criteria (at time of enrolment) will be:
* At least 18 years of age
* 17 to 24 completed weeks of gestation
* Intends to permanently reside in the trial catchment area for at least 18 months
* Family plans to reside in catchment area for the first 6 months postnatal
* Provides written informed consent for participation

Exclusion Criteria:

* Mother withdrawn from MDIG trial prior to delivery
* Failure to provide consent for participation in sub-study
D: Inclusion Criteria:

Mother:

* Pregnant in week 22-26 of gestation
* Participating in the ABC-cohort
* Living in Sealand, Denmark
* Fluent in Danish
* Willing to let the child participate in the study

Exclusion Criteria:

Mother:

* Intake of more than 400 IU of vitamin D during the last 6 months
* Endocrinological disease such as calcium metabolic disorder, parathyroid disorder, thyroid disorder or Diabetes type 1
* Tuberculosis
* Sarcoidosis
* In need of diuretics or heart medication including calcium channel blockers

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Combined Intensive and Conventional Exercise Intervention of Nonalcoholic Fatty Liver Disease
Brief Summary: The prevalence of NAFLD is 50-70% in obese people. A decrease of calorie intake and increase of physical activity are recommended as an effective approach for the prevention and treatment of NAFLD. However, the exercise model for NAFLD intervention is understudied. In the present study we aim to compare the effect of intensive and conventional exercise interventions on NAFLD.


Options:
A: Inclusion Criteria:

Member of staff at the Northern Ireland Civil Service

Exclusion Criteria:

Physically active (defined as compliance with current physical activity guidelines (Pate, 1995), age \> 65 years, resting BP \> 159/99 mm Hg, total cholesterol \> 6.2 mmol•L-1, fasting blood glucose \> 7.0 mmol•L-1, body mass index (BMI) \> 34.9 kg•m-2, current cigarette smokers, individuals with cardiovascular, pulmonary or metabolic disease, pain or discomfort in the chest, dizziness or heart murmur.

individuals taking medication known to interfere with lipid metabolism, females who were pregnant or planning to become pregnant in the following five months
B: Inclusion Criteria:

* office worker

Exclusion Criteria:

* life threatening disease
* pregnancy
C: 1. Subjects with NAFLD determined by MRS ;
2. Age 40-65 years old;
3. Waist circumference\> 90cm for men and \> 85cm for women.
D: Inclusion Criteria:

* age 18 to 80
* normal glucose tolerance, impaired glucose tolerance, or type 2 diabetes (as evidenced by use of oral hypoglycemic medication or 2-hour OGTT glucose \> 11.1 mmol/l)

Exclusion Criteria:

* Insulin treatment or type 1 diabetes
* BMI \<19 or \>40
* Physically active
* Undergoing weight-loss/gain
* Pregnancy
* Contraindication to exercise (ECG/CPX)
* Significant cardiovascular disease
* History of renal/hepatic/gastrointestinal/pulmonary disease
* Clotting or bleeding disorders

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Prevention of Adverse Pregnancy Outcome With Vitamin D Supplementation During Pregnancy
Brief Summary: We hypothesized that vitamin D supplementation during pregnancy can prevent adverse pregnancy outcome.


Options:
A: Inclusion Criteria:

* Pregnant women attending antenatal clinic at ≤ 20 weeks of gestation
* Normoglycemic, normotensive at the time of antenatal booking

Exclusion Criteria:

* Multiple pregnancy
* H/O hypertensive disorders in previous pregnancy
* Known diabetic or h/o gestational diabetes in previous pregnancy
* H/O endocrine disorders ( thyroid, parathyroid dysfunction)
* Chronic renal diseases
* Tuberculosis
* Breast feeding (current)
B: Inclusion Criteria:

* Infants born to women enrolled in the MDIG trial (NCT01924013).
* Maternal inclusion criteria (at time of enrolment) will be:
* At least 18 years of age
* 17 to 24 completed weeks of gestation
* Intends to permanently reside in the trial catchment area for at least 18 months
* Family plans to reside in catchment area for the first 6 months postnatal
* Provides written informed consent for participation

Exclusion Criteria:

* Mother withdrawn from MDIG trial prior to delivery
* Failure to provide consent for participation in sub-study
C: Inclusion Criteria:

Mother:

* Pregnant in week 22-26 of gestation
* Participating in the ABC-cohort
* Living in Sealand, Denmark
* Fluent in Danish
* Willing to let the child participate in the study

Exclusion Criteria:

Mother:

* Intake of more than 400 IU of vitamin D during the last 6 months
* Endocrinological disease such as calcium metabolic disorder, parathyroid disorder, thyroid disorder or Diabetes type 1
* Tuberculosis
* Sarcoidosis
* In need of diuretics or heart medication including calcium channel blockers
D: Inclusion Criteria:

* Women who are within the ages of 18-45 years
* In good general health
* 12 weeks pregnant (based on last menstrual period)

Exclusion Criteria:

* Mothers with preexisting type I or type II diabetes
* Mothers with preexisting hypertension
* Mothers with preexisting parathyroid disease or uncontrolled thyroid disease
* Mothers with multiple fetuses (e.g., twins, triplets, etc.)

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Cluster-Randomized Clinical Trial Of Two Educational Strategies In Cardiovascular Health (CVH) In Child Population. The Savinghearts Project
Brief Summary: AIM: To evaluate the effectiveness of two strategies in cardiovascular risk in children 2º grade in the community of Madrid.

DESIGN: cluster-randomized trial with blinded evaluator SCOPE AND SUBJECTS OF STUDY: Children of both sexes enrolled in 2º grade in public schools in the community of Madrid. Rate exclusion criteria INTERVENTION: Schools were randomly assigned to two groups: an experimental group that the investigators organized a concert teaching focused on messages cardio, a second group or control group to which they will host a healthy breakfast as it has been offering the Community of Madrid .

MEASUREMENTS: The primary end result is the increase of correct answers on a standardized test to be administered before and after the activity.

Secondary outcomes will be, improving the same questionnaire at 6 months and reduced overall weight and center from before the intervention at 6 months of it.


Options:
A: Inclusion Criteria:

* Girls had to be attending members of Girl Scouts in one of our included troops.
* The troop needed to be a registered Girl Scouts Juniors troop, consisting of girls primarily in the 4th and 5th grades.
* To be officially registered, the troop leaders were required to complete Girl Scout leader training and pass a criminal background check.
* To be included, the troops also needed to meet at least twice per month, have meeting facilities capable of allowing physical activity and food preparation.
* Also, troops needed to have initial agreement of leaders and parents for the troop to participate in a research study.

Exclusion Criteria:

* An inability to speak or read English.
* Troops not primarily composed of Girl Scouts Juniors, not regularly meeting during the study period, or not having leader and parental consensus approval for troop participation.
B: Inclusion Criteria:

* Obese children

Exclusion Criteria:

* Other chronic medical conditions
* Medical intake
C: Inclusion Criteria:

* 2º grade of primary school students present the day of the activity, whose parents had signed the informed consent to participate in the study and with no exclusion criteria at the moment of the intervention

Exclusion Criteria:

* Students with food allergies or intolerances.
* Students with severe hearing impairment (not corrected).
* Students whose parents didn´t sign the informed consent to participate in the study.
* Students with a poor understanding of oral and written language.
* To have previously received healthy breakfasts interventions or educational concerts.
D: Inclusion Criteria:

* Latino parents with children ages 3-5
* parent agrees to participate in all sessions
* parent can be reached via telephone contact over next 3 months

Exclusion Criteria:

* non-Latino parents
* children outside target age range
* parent not agreeing to participate in all sessions
* parent cannot be reached via telephone contact over next 3 months

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Programming by Estrogen Treatment in Gonadotropin Releasing Hormone Antagonist Protocol
Brief Summary: The purpose of this study is to determine if pretreatment with Estrogen can assist in the planning and programming of In Vitro Fertilization treatments.


Options:
A: Inclusion Criteria:

* All patients referred for infertility receiving their first IVF or IVF+ICSI treatment

Exclusion Criteria:

* Previous IVF or IVF+ICSI-treatment
* Uterine anomalies
* It is necessary to perform direct sperm aspiration from husband's/partner's testicles
* Allergy to one of the intervention products
* Patient is 40 years or above
B: Inclusion Criteria:

* women of good physical and mental health
* under 37 years old, with regular menstrual cycles of 25-35 days
* normal basal FSH and LH levels
* BMI less than 30 kg/m2
* presence of both ovaries and intact uterus
* absence of polycystic ovaries
* endometriosis, or gynaecological / medical disorders and a negative result in a screening for sexually transmitted diseases
* all patients signed a written informed consent form
* no patient had received any hormone therapy for at least 60 days preceding the study.
C: Inclusion Criteria:

* Puregon® (recFSH)/Orgalutran® group:

  * Women with a pregnancy of \>= 16 weeks after Puregon® /Orgalutran® treatment for IVF or ICSI and ET of fresh embryos. Treatment is defined as having had at least one injection of Orgalutran®.
  * Women between 18 and 39 years of age (inclusive) at the day of hCG.
  * Women who are able and willing to sign informed consent.

Controls

* Infants (gestational age \>=16 weeks) of women pregnant after COH using a GnRH agonist in a long protocol for IVF or ICSI and ET of fresh embryos.
* Infants of women between 18 and 39 years of age (inclusive) at the day of hCG.
* The most recent 1000 infants delivered prior to January 1, 2001.

Exclusion Criteria:

* None
D: Inclusion Criteria:

* IVF treatment in the following indications: Male, Mechanical, Unexplained
* Age\<38 years
* Treatment Cycle number 1-4

Exclusion Criteria:

* Ovulatory disorder as an indication for IVF
* Repeated failure in previous IVF treatments (\> than 4 cycles)
* Sperm used for treatment was retrieved by surgical procedure

Answer: D